Category Archives: HIV care & treatment

New HIV medication ibalizumab (Trogarzo) approved by the FDA for people with few treatment options

On March 6, 2018, the FDA approved a new type of HIV medication called ibalizumab for people who have few to no treatment options due to multi-drug resistant virus. The approval was based on results from the TMB-301 study that showed that adding the drug to…Read More

California HIV Alliance submits budget proposal to the state

The California HIV Alliance, of which Project Inform is a member, submitted their budget request to the State, urging the State to make strategic investments in programs that will increase PrEP uptake and other evidence-based prevention services, provide targeted HIV prevention and employment services for transgender women,…Read More

New multi-stakeholder report released on public health and HIV sequence analysis

CLICK HERE for a PDF of the report. The Third Coast Center for AIDS Research (CFAR), in collaboration with Project Inform, is pleased to publish the proceedings and recommendations from a multi-sector stakeholder consultation held on May 10 and 11, 2017, in Chicago, Illinois. The consultation…Read More

Adopting the U=U message in all we do

U=U is more than just a catchy slogan. In fact, what it stands for — the overwhelming evidence that a person with HIV who has a durably undetectable virus is virtually incapable of transmitting the virus to a partner — has finally been accepted and even…Read More

FDA approves new single tablet regimen for treating HIV, called Biktarvy

On February 7, 2018, the Food and Drug Administration approved a new single tablet regimen for treating chronic HIV infection under the brand name Biktarvy. The regimen is comprised of the new integrase inhibitor bictegravir along with two NRTIs, emtricitabine (FTC) and tenofovir alafenamide (TAF). The…Read More

FDA accepts two new drug applications for new NNRTI doravirine

The Food and Drug Administration has accepted two new drug applications (NDAs) for the HIV medication called doravirine. Doravirine is a new NNRTI or non-nucleoside reverse transcriptase inhibitor that completed two 48-week studies in 2017. If both NDAs are approved, doravirine could be available this year…Read More

Congratulations to New Program Directors, David Evans and Emalie Huriaux

Project Inform has a small and mighty group of staff — seven in total — who develop and implement our programs in three areas: research advocacy, education and public policy. Anne Donnelly has served as our Director of Health Care Policy for 10 years, leading our…Read More